Brief: Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA

Lexicon Pharmaceuticals

22/11/2024 12:36

Nov 22 (Reuters) - Lexicon Pharmaceuticals Inc  LXRX.O :
    * LEXICON TO REPOSITION AS CLINICAL DEVELOPMENT-FOCUSED
COMPANY
FOLLOWING REGULATORY UPDATE FROM FDA
    * LEXICON PHARMACEUTICALS INC: EFFORTS EXPECTED TO REDUCE
2025
OPERATING COSTS BY $100 MILLION
    * LEXICON PHARMACEUTICALS INC: PRIORITIZING STRONG RESEARCH
AND
DEVELOPMENT PIPELINE INCLUDING ONGOING STUDIES IN DPNP, HCM AND
OBESITY
    * LEXICON PHARMACEUTICALS INC: IMPLEMENTING STRATEGIC
RESTRUCTURING TO ELIMINATE COMMERCIAL ORGANIZATION AND
RATIONALIZE OPERATIONS ACROSS ALL FUNCTIONS
    * LEXICON PHARMACEUTICALS INC: TOTAL REDUCTION OF
APPROXIMATELY 60
PERCENT OF EMPLOYEES, EFFECTIVE FOR MOST AFFECTED EMPLOYEES BY
DECEMBER 31
    * LEXICON PHARMACEUTICALS INC:  ELIMINATION OF PROMOTIONAL
EFFORTS
FOR INPEFA, PLANNED COMMERCIAL ACTIVITIES FOR ZYNQUISTA
    * LEXICON PHARMACEUTICALS INC:  RECEIPT OF A "DEFICIENCIES
PRECLUDE DISCUSSION" LETTER FROM FDA REGARDING NDA FOR ZYNQUISTA

Source text:  ID:nGNXnl2zP 
Further company coverage:  LXRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))